Compounds, compositions and methods
By providing small molecule calcitonin and amylin receptor modulators, these receptors are activated, solving the problem of poor regulatory effects in existing technologies and achieving effective treatment for obesity and diabetes.
CN122319145APending Publication Date: 2026-06-30ACONCAGUA BIOTECH
Patent Information
- Application Number
- CN202480058356.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-06-06
- Filing Date
- 2024-07-12
- Publication Date
- 2026-06-30
AI Technical Summary
Technical Problem
Existing technologies have difficulty effectively modulating calcitonin and amylin receptors, resulting in poor efficacy of therapies for metabolic disorders such as obesity and diabetes.
Method used
We provide small molecule calcitonin and amylin receptor modulators, including compounds and pharmaceutical compositions, for activating these receptors to improve metabolic function.
Benefits of technology
By activating calcitonin and amylin receptors, it significantly improves glycemic regulation and weight management, providing an effective treatment for obesity and diabetes.
✦ Generated by Eureka AI based on patent content.
Smart Images

Figure CN122319145A_ABST
Abstract
This application discloses compounds of formula I for modulating the activity of calcitonin receptors and / or amylin receptors, as well as pharmaceutical compositions comprising the compounds disclosed herein. Methods for treating diseases or disorders related to calcitonin receptors and / or amylin receptors are also provided.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Reduced moisture chemical reactions
IN256918B
Anti-nausea drug combinations
US10071088B2
Combinations of amisulpride and another anti-emetic for treating nausea and vomiting
US10322106B2
Use of amisulpride as an anti-emetic
US10525033B2
Compositions and methods for treating centrally mediated nausea and vomiting
US10828297B2